Supernus Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for central nervous system (CNS) diseases.
Its marketed portfolio covers:
- ADHD (Qelbree)
- Dyskinesia in Parkinson's patients on levodopa (GOCOVRI)
- Motor fluctuations/hypomobility in advanced Parkinson's disease (ONAPGO, APOKYN)
- Postpartum depression (ZURZUVAE)
- Epilepsy and migraine (Trokendi XR, Oxtellar XR)
- Cervical dystonia and chronic sialorrhea (MYOBLOC)
- Other products including XADAGO and Osmolex ER
ZURZUVAE, gained through the July 2025 acquisition of Sage Therapeutics, is commercialized with Biogen; Supernus records 50% of Biogen's U.S. net revenue as collaboration revenue. The company also earns royalty and licensing revenue, including royalties on generic versions of Trokendi XR and Oxtellar XR, which face generic competition.
Its clinical pipeline includes:
- SPN-817, a selective AChE inhibitor for treatment-resistant focal seizures (Phase 2b)
- SPN-820, an mTORC1 activator for major depressive disorder (Phase 2b)
- SPN-443, a novel ADHD stimulant (Phase 1 planned)
Supernus agreed to an all-stock merger with Indivior Pharmaceuticals, expected to close November 2, 2026. The combined company, Supernus, Inc., will trade on Nasdaq under the ticker SUPN. Updated
Supernus Pharmaceuticals is handing shareholders $473 million, or $8.13 a share, on November 6, dwarfing everything else being paid today. The rest are bank dividends measured in cents: First Interstate BancSystem is next at $44 million.